Subsidy Information and Financing Scheme SDLPanitumumab (Vectibix) Concentrate For Infusion 100 mg/5 mL MSHLPanitumumab Concentrate For Solution For Infusion 100 mg/5 mL For cancer treatment.
Drug Guidance for Subsidy 12/07/2022 Cetuximab and panitumumab for treating RAS wild-type colorectal cancer The Ministry of Health’s Drug Advisory Committee has recommended: Cetuximab 100 mg/20 mL solu... See all × 12/07/2022 Cetuximab and panitumumab for treating RAS wild-type colorectal cancer The Ministry of Health’s Drug Advisory Committee has recommended: Cetuximab 100 mg/20 mL solution for infusion; and Panitumumab 100 mg/5 mL concentrate for solution for infusion as monotherapy or in combination with chemotherapy for treating RAS wild-type metastatic colorectal cancer. Subsidy status RPanitumumab 100 mg/5 mL concentrate for solution for infusion is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indication with effect from 4 January 2022. RCetuximab 100 mg/20 mL solution for infusion is recommended for inclusion on the SDL for the abovementioned indication with effect from 1 September 2022. Clinical indications, subsidy class and MediShield Life claim limits for both drugs are provided in the Annex.
Post Marketing Information DHCPL 05/05/2014 Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients treated with Vectibix™ (panitumumab)
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Vectibix Concentrate For Infusion 100 mg/5 mL Khoo Teck Puat Hospital National Cancer Centre Ng Teng Fong General Hospital National University Hospital Tan Tock Seng Hospital
INTRAVENOUS Select a brand starting with the letter: V VECTIBIX CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/VIAL [SIN14498P]